Clinical trials · Washington
Metastatic Lung Cancer clinical trials in Washington
We’re tracking 110 recruiting metastatic lung cancer studies with a site in Washington — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Washington
- NCT07488923RecruitingPhase 1
ML261 CAR T therapy for advanced small cell lung cancer and related neuroendocrine cancers
This trial tests a new treatment called ML261, which uses your own immune cells (T cells) that have been modified to target DLL3, a protein found on certain cancer cells. It is for people with advanced small cell lung cancer or other neuroendocrine cancers that have not responded to standard treatments.
Seattle, WashingtonAges 18 years+ - NCT06765109RecruitingPhase 3
Testing neladalkib for untreated ALK-positive lung cancer
This study tests a new pill called neladalkib to see if it works better than the current standard treatment (alectinib) for people with ALK-positive lung cancer who have not yet received any cancer therapy for advanced disease. It may be a good option if you have ALK-positive NSCLC and have not been treated before.
Seattle, WashingtonAges 18 years+ - NCT06357533RecruitingPhase 3
New drug combo for advanced lung cancer with high PD-L1
This trial tests a new two-drug combination (Dato-DXd and an immunotherapy called rilvegostomig) as the first treatment for people with advanced non-squamous lung cancer who have high PD-L1 levels. The goal is to see if this combination works better than current standard options.
Tacoma, WashingtonAges 18 years+ - NCT05245500RecruitingPhase 1
Study drug for solid tumors with MTAP gene deletion
This Phase 1 trial studies MRTX1719, a new medicine, in solid tumors that have a missing MTAP gene (MTAP deletion). It aims to find the safest dose and check how the drug affects the tumor.
Seattle, WashingtonAges 18 years+ - NCT05236114Recruiting
Study of blood and tumor tests for lung cancer treatment
This study looks at how tumor and blood biomarker results can guide treatment for people with non-small cell lung cancer (NSCLC). Depending on the cancer stage, it may follow standard-of-care treatment plans around surgery or first-line immunotherapy.
Bellingham, WashingtonAges 18 years+ - NCT05646862RecruitingPhase 3
Comparing two treatments for advanced breast cancer with a PIK3CA mutation
This trial tests whether a new drug combo (inavolisib plus fulvestrant) works better than an existing one (alpelisib plus fulvestrant) for people with a specific type of advanced breast cancer that has a PIK3CA mutation. It aims to find a treatment that may help control the cancer longer.
Kennewick, WashingtonAges 18 years+ - NCT07222800RecruitingPhase 3
Testing a new drug plus chemo for stage 4 colorectal cancer
This study tests a new experimental drug (PF-08634404) combined with standard chemotherapy for people with stage 4 colorectal cancer who have not yet been treated for their advanced disease. The goal is to see if the combination helps shrink or slow the growth of tumors.
Bonney Lake, WashingtonAges 18 years+ - NCT07006727RecruitingPhase 1
Study of a new drug for advanced DLL3-positive solid tumors
This trial tests an experimental treatment for several types of advanced cancer that have stopped responding to standard therapy. The drug targets a protein called DLL3 found on some tumor cells, which may help slow or stop tumor growth.
Seattle, WashingtonAges 18–100 - NCT05058651RecruitingPhase 2/Phase 3
Atezolizumab plus chemo for advanced neuroendocrine cancer outside the lung
This trial tests whether adding an immunotherapy drug called atezolizumab to standard chemotherapy helps people with advanced neuroendocrine carcinoma (a rare and aggressive cancer) that started outside the lung. The goal is to see if the combination works better than chemo alone.
Seattle, WashingtonAges 18 years+ - NCT06863272RecruitingPhase 1/Phase 2
Study of ifinatamab deruxtecan for advanced prostate cancer
This trial tests a new drug, ifinatamab deruxtecan, either alone or in combination with other treatments, for men with metastatic castrate-resistant prostate cancer that has worsened despite hormone therapy. It aims to see if this approach can help shrink or slow the cancer.
Seattle, WashingtonAges 18 years+ - NCT06662786RecruitingPhase 3
Amivantamab plus chemo vs. standard chemo for left-sided colorectal cancer
This trial compares a new combination (amivantamab plus chemotherapy) with the standard treatment (cetuximab plus chemotherapy) as the first therapy for people with left-sided colorectal cancer that has spread. The goal is to see which approach works better when the tumor has no mutations in the KRAS, NRAS, or BRAF genes.
Edmonds, WashingtonAges 18 years+ - NCT06731478RecruitingPhase 3
New drug combo for first treatment of HER2-positive stomach cancer
This trial tests a new targeted drug (TDXd) combined with chemotherapy, pembrolizumab, and trastuzumab for people with HER2-positive stomach or gastroesophageal junction cancer that has spread or cannot be removed by surgery. It aims to see if this combination works better than standard treatments as a first therapy.
Wenatchee, WashingtonAges 18 years+ - NCT03866382RecruitingPhase 2
Immunotherapy plus a targeted drug for rare genitourinary tumors
This Phase 2 study tests whether nivolumab and ipilimumab (immunotherapy drugs) plus cabozantinib (a targeted anti-cancer drug) can shrink or control rare cancers of the urinary/reproductive system that have spread. It may help by boosting the immune system and blocking cancer growth signals at the same time.
Aberdeen, WashingtonAges 18 years+ - NCT04389632RecruitingPhase 1
Sigvotatug vedotin for advanced solid tumors that spread
This early-stage study tests a drug called sigvotatug vedotin in people with advanced solid cancers that cannot be removed or have spread. It aims to see how well the treatment works and what side effects it causes.
Bonney Lake, WashingtonAges 18 years+
Metastatic Lung Cancer trials by city in Washington
Where these studies are running in Washington
Institutions with a site for the recruiting metastatic lung cancer studies listed above.
- Fred Hutchinson Cancer Center · 6 studies
- Swedish Medical Center · 4 studies
- Kadlec Clinic Hematology and Oncology · 3 studies
- Northwest Medical Specialties · 2 studies
- Swedish Cancer Institute-Edmonds · 2 studies
- American Oncology Network Vista Oncology Division-East office
- American Oncology Network Vista Oncology Division-West office
- Cancer Care Northwest
What taking part in a metastatic lung cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Metastatic Lung Cancer trials in other states
Common questions
- Are there metastatic lung cancer clinical trials in Washington?
- Yes. We're currently tracking 110 recruiting metastatic lung cancer studies with a site in Washington, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a metastatic lung cancer study in Washington?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Washington to take part?
- Not necessarily. These studies have a site in Washington, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a metastatic lung cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New metastatic lung cancer studies open in Washington regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.